17,261 trials
Metastatic Pancreatic Adenocarcinoma · Metastatic Pancreatic Cancer
Primary: Regimen Limiting Toxicity — 0; 0; 0 Participants
Dementia With Lewy Bodies
Primary: Safety and Tolerability: Occurrence of Adverse Events (AEs) — 2; 2; 74; 37 events
Parkinson Disease
Primary: Gait Speed — 1.09; 1.04; 1.15; 1.08 meters per second
Hematologic Neoplasm · Neoplasms · Hematologic Malignancies
Primary: Number of Participants With Treatment Emergent Adverse Events — 1; 1; 1; 1 Participants
Mild Cognitive Impairment · Cognitive Impairment
Primary: Cerebrospinal Fluid Insulin Levels — 0.11; 0.15; 0.14; 0.26 micro units/mL
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · HNSCC for Phase 2 Dose Expansion · NSCLC for Phase 2 Dose Expansion
Primary: Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 1; 3; 5 Participants
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) Percent Predicted — 65.6; 66.0; 70; 69.5 percent predicted — p=0.447
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
IgG4 Related Disease
Primary: Volume of the Submandibular Glands on PET-MRI — 12.7; 9.34; -3.37 cm^3 — p=< 0.001
Chronic Pain
Primary: PROMIS Pain Interference Scale - Short Form 6b — 62.1; 62.1; 62.8; 60.8 T-score - difference scores between arms
Type1diabetes
Primary: Insulin Sensitivity — 5.71; 6.02 mg/kg/min
Recurrent Prostate Cancer
Primary: Changes in Fatigue — 52.4; 53.4 T-score — p=0.454
Mild Cognitive Impairment · Herpes Simplex 1 · Herpes Simplex 2
Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio
Pancreas Cancer
Primary: Disease Control Rate (DCR) — 0 DCR, % of participants with CR/PR/SD
Asthma
Primary: Annualized Rate of Severe Asthma Exacerbation Events Over 48 Weeks — 0.598; 0.463; 0.312; 0.450 exacerbation/participant-year — p=0.3626